Serum of NTN4 and MDP1 in elderly patients with acute cerebral infarction with early neurological deterioration and prognosis
Journal of Medical Biochemistry · 2026 · (00) · 208-208
DOI: 10.5937/jomb0-65158 ↗Abstract
Background: To investigate the levels of neurotrophic factor 4 (NTN4) and male differentially expressed protein 1 (MDP1) in elderly patients with acute cerebral infarction (ACI), and to assess their association with early neurological deterioration and prognosis. Methods: From February 2023 to December 2025, 240 patients with ACI admitted to this hospital composed the observation group. The patients were categorized into a severe group (NIHSS score > 15) and a mild group (NIHSS score < 15) based on the National Institutes of Health Stroke Scale (NIHSS) score; they were further classified into a poor prognosis group (grades 3-6) and a good prognosis group (grades 0-2) using the modified Rankin scale. A control group of 240 healthy adults was selected, all of whom completed physical tests at the same hospital over the same timeframe. Serum levels of MDP1 and NTN4 were measured in each research participant using an enzyme-linked immunosorbent assay. In individuals with acute cerebral infarction (ACI), the association between serum NTN4 and MDP1 levels was examined using Pearson's correlation. Factors influencing poor prognosis in ACI patients were also identified using multivariate logistic regression. The ability of serum NTN4 and MDP1 to predict a poor outcome in individuals with ACI was assessed using receiver operating characteristic (ROC) curves. Results: While albumin (ALB) and NTN4 serum levels were considerably lower in the observation group than in the control group, MDP1 and creatinine serum levels were significantly higher. P<0.05 indicates that the differences were statistically significant. Serum NTN4 levels were significantly greater in the mild group than in the severe group, and serum MDP1 levels were significantly lower in the mild group than in the severe group (P<0.05). Although the serum creatinine and MDP1 levels were lower than those in the good prognosis group, the maximum diameter of the lesion was larger in the poor prognosis group than in the good prognosis group. Additionally, the serum ALB and NTN4 levels were lower than those in the good-prognosis group. The statistical significance of all the differences was established by P<0.05. According to Pearson's correlation analysis, there was a negative association between blood MDP1 levels and serum NTN4 levels in ACI patients (r=-0.510; P<0.001). A multivariate logistic regression analysis indicated that increased serum NTN4 levels were an independent protective factor for a favourable prognosis in ACI patients (P<0.05). A larger maximum lesion diameter, elevated serum creatinine and ALB levels, and elevated serum MDP1 levels were independent risk factors for poor prognosis in ACI patients (P<0.05). The ROC curve analysis indicated that the area under the curve (AUC) for the joint prediction of serum NTN4 and MDP1 in forecasting poor prognosis in patients with ACI was 0.913, which was greater than the AUC of the two predictors alone (0.857 and 0.830), and the differences were statistically significant (Z=2.109 and 2.730, respectively; P<0.05). Conclusion: Serum NTN4 levels are decreased in patients with ACI, whereas MDP1 levels are increased. Both parameters are closely associated with the prognosis of ACI patients. They may serve as reference values for predicting their outcomes.
EUVIMED